FHIR IG analytics
- Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
- Authority: All | hl7 | ihe | national
- Realm: All | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | pt | se | stt | tw | uk | us | uv
- View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps
Resources - All Kinds, Authority Hl7
By Version
By Realm
Start Prev Rows 9400 - 9600 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Usage # |
|---|---|---|---|---|---|---|---|---|---|
| fhir.tx.support | R5 | ConceptMap/ConceptMap-resource-names-r3-r4.json | Resource Names R3 to R4 | active | 2019-01 | us | |||
| fhir.tx.support | R5 | ConceptMap/ConceptMap-resource-names-r4-r2.json | Resource Names R4 to R2 | active | 2019-01 | us | |||
| fhir.tx.support | R5 | ConceptMap/ConceptMap-resource-names-r4-r3.json | Resource Names R4 to R3 | active | 2019-01 | us | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsAdministrative2Fhir.json | EMS Administrative to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsAnamnesis2Fhir.json | EMS Anamnesis to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsDiagnosis2Fhir.json | EMS Diagnosis to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsEventOfDeath2Fhir.json | EMS Event of Death to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsFindings2Fhir.json | EMS Findings to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsHandover2Fhir.json | EMS Handover to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsAnnotation2Fhir.json | EMS Annotation to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsMission2Fhir.json | EMS Mission to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsPatient2Fhir.json | EMS Patient to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsPretreatment2Fhir.json | EMS Pretreatment to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsProcedures2Fhir.json | EMS Procedures to FHIR Mapping | active | 2026-10 | ch | |||
| ch.fhir.ig.ch-ems | R4 | ConceptMap/ConceptMap-EmsTransport2Fhir.json | EMS Transport to FHIR Mapping | active | 2026-10 | ch | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-bio-sample-lm-to-fhir.json | BioSample logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-clinical-event-lm-to-fhir.json | ClinicalEvent logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-clinical-event-type-lm-to-fhir.json | ClinicalEventType logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-clinical-variable-lm-to-fhir.json | ClinicalVariable logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-concomitant-medication-lm-to-fhir.json | ConcomitantMedication logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-donor-lm-to-fhir.json | Donor logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-imm-pat-lm-to-fhir.json | ImmPat logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-immunological-data-lm-to-fhir.json | Immunological Data logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-immunosuppressant-lm-to-fhir.json | Immunosuppressant logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-instrumental-investigation-lm-to-fhir.json | InstrumentalInvestigation logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-lab-result-lm-to-fhir.json | LabResult logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-lab-test-lm-to-fhir.json | LabTest logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-microbiology-lm-to-fhir.json | Microbiology logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-patient-lm-to-fhir.json | Patient logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-pre-medication-lm-to-fhir.json | PreMedication logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-transplant-lm-to-fhir.json | Transplant logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-visit-lm-to-fhir.json | Visit logical model → FHIR | draft | 2026-09 | eu | |||
| hl7.eu.fhir.protect-child | R4 | ConceptMap/ConceptMap-vital-sign-lm-to-fhir.json | Vital Sign logical model → FHIR | draft | 2026-09 | eu | |||
| uk.nhsdigital.r4.test | R4 | ConceptMap/issueType-to-http-status-code.json | issueType-to-http-status-code | draft | 2020-08 | ||||
| hl7.fhir.eu.health-data-api | R4 | ConceptMap/ConceptMap-document-reference-category-type-eu-api.json | EEHRxF MHD DocumentReference ConceptMap | draft | 2026-09 | eu | |||
| hl7.fhir.uv.ihe-sdc-ecc | R4 | ConceptMap/ConceptMap-conceptMapCAPex.json | Example CAP Concept Map of SNOMED to CAP eCP content identifiers | draft | 2022-04 | uv | |||
| uk.nhsdigital.r4.test | R4 | ConceptMap/organisation-role-to-organisation-type.json | organisation-role-to-mim-organisation-type | draft | 2020-08 | ||||
| ru.core | R5 | ConceptMap/ConceptMap-core-cm-nsi-time-to-fhir.json | Единицы времени НСИ — единицы расписания FHIR | draft | 2026-09 | ||||
| hl7.fhir.us.ph-bulk-data | R4 | ExampleScenario/ExampleScenario-phBulkExportExampleScenario.json | PublicHealthBulkExportExample | active | pher | 2026-06 | us | ||
| hl7.fhir.us.ph-query | R4 | ExampleScenario/ExampleScenario-phQueryExampleScenario.json | QueryWithIntermediary | active | pher | 2026-06 | us | ||
| hl7.fhir.us.ph-query | R4 | ExampleScenario/ExampleScenario-phQueryExampleScenarioDirect.json | QueryWithoutIntermediary | active | pher | 2026-06 | us | ||
| hl7.fhir.test.multi-lang | R4 | ExampleScenario/ExampleScenario-example.json | ExampleExampleScenario | draft | fhir | 2025-08 | test | ||
| fhir.nwgenomics.nhs.uk | R4 | ExampleScenario/ExampleScenario-BiopsyProcedure.json | BiopsyProcedure | draft | 2026-10 | us | |||
| fhir.nwgenomics.nhs.uk | R4 | ExampleScenario/ExampleScenario-ClinicalAndGenomicWorkflow.json | ClinicalAndGenomicWorkflow | draft | 2026-10 | us | |||
| fhir.nwgenomics.nhs.uk | R4 | ExampleScenario/ExampleScenario-GenomicTestOrderProcess.json | GenomicTestOrder | draft | 2026-10 | us | |||
| fhir.nwgenomics.nhs.uk | R4 | ExampleScenario/ExampleScenario-GenomicTestReportProcess.json | GenomicTestReport | draft | 2026-10 | us | |||
| hl7.fhir.us.physical-activity | R4 | ExampleScenario/ExampleScenario-Scen1ExercisePrescriptionScenario.json | ExercisePrescription | draft | pc | 2024-03 | us | ||
| hl7.fhir.us.physical-activity | R4 | ExampleScenario/ExampleScenario-Scen2ProviderToPersonaltrainerReferral.json | ProviderToPersonalTrainerReferral | draft | pc | 2024-03 | us | ||
| hl7.fhir.us.physical-activity | R4 | ExampleScenario/ExampleScenario-Scen3ProviderToYMCAReferral.json | PatientSeeksReferralforExerciseProgram | draft | pc | 2024-03 | us | ||
| hl7.fhir.us.physical-activity | R4 | ExampleScenario/ExampleScenario-Scen4PhysicalActivityPlan.json | PatientWorksWithPersonalTrainer | draft | pc | 2024-03 | us | ||
| hl7.fhir.us.physical-activity | R4 | ExampleScenario/ExampleScenario-Scen5ActivityAndGlucoseObservations.json | PatientProviderCommunicationonActivityandBloodGlucoseObservations | draft | pc | 2024-03 | us | ||
| hl7.fhir.us.directory-attestation | R4 | ExampleScenario/ExampleScenario-4D7XtHwNtteDczynb.json | active | 2022-12 | us | ||||
| hl7.fhir.us.directory-attestation | R4 | ExampleScenario/ExampleScenario-5psortwYNqr2vLNwQ.json | active | 2022-12 | us | ||||
| hl7.fhir.us.directory-attestation | R4 | ExampleScenario/ExampleScenario-DX6RLSCje9KkEcHRt.json | active | 2022-12 | us | ||||
| hl7.fhir.us.directory-attestation | R4 | ExampleScenario/ExampleScenario-N4qis3v6pkhtJrPFK.json | active | 2022-12 | us | ||||
| hl7.fhir.us.directory-attestation | R4 | ExampleScenario/ExampleScenario-PAsijcfHEKD9siu4h.json | active | 2022-12 | us | ||||
| hl7.fhir.us.directory-attestation | R4 | ExampleScenario/ExampleScenario-RsW5oCHfnQejTw9Jd.json | active | 2022-12 | us | ||||
| hl7.fhir.uv.cpg | R4 | GraphDefinition/GraphDefinition-chf-caseplansummarydefinition.json | CHFCasePlanSummaryDefinition | active | uv | ||||
| hl7.fhir.uv.cpg | R4 | GraphDefinition/GraphDefinition-chf-casesummarydefinition.json | CHFCaseSummaryDefinition | active | uv | ||||
| hl7.fhir.uv.crmi | R4 | GraphDefinition/GraphDefinition-publishable-example.json | PublishableGraphDefinitionExample | draft | 2021-02 | uv | |||
| hl7.fhir.uv.crmi | R4 | GraphDefinition/GraphDefinition-shareable-example.json | ShareableGraphDefinitionExample | draft | 2021-02 | uv | |||
| hl7.fhir.be.referral | R4 | GraphDefinition/GraphDefinition-full-referral-prescription.json | FullReferralPrescription | active | 1 | 2024-09 | be | ||
| hl7.fhir.uv.api-incubator | R6 | GraphDefinition/GraphDefinition-example.json | Document Generation Template | draft | 2015-08 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-179619.json | SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179897.json | ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59 | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-172424.json | ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD) | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-264328.json | Search Strategy for NMA_Diabetes | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-172423.json | ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179514.json | ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179513.json | ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179510.json | ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179509.json | ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179375.json | ConceptualCohortDefinition: Severe obesity | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179376.json | ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179508.json | ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179512.json | ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179506.json | ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-170441.json | ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years | active | 2022-09 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-170442.json | ConceptualCohortDefinition_Cardiovascular_event | active | 2022-09 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-179786.json | ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179785.json | ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-173252.json | OutcomeDefinition: Diabetes in remission | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179799.json | MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-264323.json | Eligibility criteria for NMA_Diabetes | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-375279.json | Adverse event free and hypertension control | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179593.json | SearchStrategy: PubMed search for Wonder Woman | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179507.json | ConceptualCohortDefinition: Proxy criteria for surgical candidates | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-172484.json | OutcomeDefinition: HbA1c at 12 months | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-172477.json | OutcomeDefinition: HbA1c at 24 months | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-173245.json | OutcomeDefinition: HbA1c at 36 months | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-175762.json | OutcomeDefinition: HbA1c at 6 months | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-172476.json | OutcomeDefinition: HbA1c at 60 months | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-367881.json | NCT03640312 Eligibility Criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-267225.json | NCT03421379 Eligibility Criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-583769.json | NCT05327010 Eligibility Criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-189713.json | NCT04401202 Eligibility Criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-175765.json | MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-279340.json | ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-173251.json | OutcomeDefinition: New onset depression | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-173249.json | ConceptualCohortDefinition: Nonfatal myocardial infarction | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-173250.json | ConceptualCohortDefinition: Nonfatal stroke | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-173248.json | OutcomeDefinition: Nonfatal myocardial infarction or stroke | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179562.json | EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179783.json | Remdesivir IV 200 mg once then 100 mg once daily for 9 days | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-265092.json | Diabetes treatment medication | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-175766.json | MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-33395.json | MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis | active | 2022-05 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-172480.json | OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236530.json | ComparatorDefinition: Standard care | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236532.json | InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236533.json | Adults with type 2 diabetes and established CVD (but no CKD) | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236769.json | InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236776.json | ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236947.json | Adults with type 2 diabetes and CVD and CKD | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-282882.json | NHANES LBXGLU Variable Definition Cohort Definition | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-282891.json | NHANES LBDGLUSI Variable Definition Cohort Definition | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-282899.json | NHANES WTSAF2YR Variable Definition Cohort Definition | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-291368.json | OutcomeDefinition: Mortality at 14 days | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-346486.json | CTIS2024-516402-32-00 Eligibility Criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-588218.json | PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179633.json | ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179902.json | ConceptualCohortDefinition: At least 2 risk factors for stroke | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-297488.json | Jumping from aircraft with empty backpack | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179584.json | NetEffectContributions: Bariatric Surgery Example for GIN 2022 | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-297486.json | Jumping from aircraft with parachute | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-297750.json | OutcomeDefinition: Injury Severity Score on Impact | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179592.json | SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-270503.json | ConceptualCohortDefinition: T1DM or T2DM | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-279347.json | ConceptualCohortDefinition: T1DM-specific criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-279346.json | ConceptualCohortDefinition: T2DM-specific criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-267506.json | M11 IGBJ Protocol Example Eligibility Criteria | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179900.json | ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-179898.json | ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-33398.json | StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis | active | 2022-05 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-7749.json | Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill | active | 2021-08 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-7750.json | Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill | active | 2022-01 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-32145.json | StudyGroup: Diabetes Surgery Study Trial Enrollment Group | active | 2022-05 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-46117.json | StudyGroup_DIBASY_Trial_Enrollment_Group | active | 2022-05 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-265093.json | Adults with diabetes mellitus type 2 | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-178427.json | StudyGroup: Severely Obese Adults 2018 Norwegian Cohort | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-307440.json | PARACHUTE Trial non participants | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-306658.json | Analyzed Group in PARACHUTE Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-306660.json | Group Randomized to Comparator (empty backpack) in PARACHUTE Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-370702.json | Glucagon Hydrochloride Solution (Active Comparator) | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-370701.json | Glucagon Nasal Powder (Experimental) | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-306657.json | Enrolled Group PARACHUTE Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-375175.json | QUARTET USA Trial Quadpill group | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-306659.json | Group Randomized to Intervention Group (parachute) in PARACHUTE Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-306655.json | Screened Group PARACHUTE Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-372797.json | Enrolled Group for QUARTET USA Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-172939.json | ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-172934.json | ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236535.json | GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236948.json | MAGICapp-derived Group: GLP-1 RA Group in Adults with type 2 diabetes | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-557018.json | GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-557341.json | GLP-1 RA Group in Adults with type 2 diabetes | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-372778.json | Eligibility Criteria for QUARTET USA Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-170443.json | StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study | active | 2022-09 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-179511.json | Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17) | active | 2022-06 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-32139.json | RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16) | active | 2022-06 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-172461.json | StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-236949.json | SGLT2 inhibitors Group in Adults with type 2 diabetes | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-557342.json | SGLT2 inhibitors Group in Adults with diabetes mellitus type 2 | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-557017.json | Standard care Group in Adults with type 2 diabetes with moderate CV risk | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-375182.json | QUARTET USA Trial Control Group | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-5224.json | NCT04401202_Enrollment_Group | active | 2021-10 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-172460.json | ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-12714.json | Adults hospitalized with COVID-19 pneumonia | active | 2021-08 | uv | |||
| hl7.fhir.uv.ebm | R6 | Group/Group-179901.json | ConceptualCohortDefinition: Heart failure based on Phenotypes | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-297487.json | PARACHUTE trial participants assigned parachute | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-297489.json | PARACHUTE Trial Participants assigned an empty backpack | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-292955.json | PARACHUTE Trial Participants | active | uv | ||||
| hl7.fhir.uv.ebm | R6 | Group/Group-171819.json | StudyEligibilityCriteria: Obese patients ≥ 18 years old | active | uv | ||||
| hl7.fhir.us.bser | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.bser.json | Bidirectional Services eReferral (BSeR) | active | 2025-04 | us | |||
| fhir.rehabig | R4 | ImplementationGuide/ImplementationGuide-fhir.rehabig.json | 復健訓練量表實作指引 (Rehabilitation Training Scale Implementation Guide) | draft | 2026-10 | us | |||
| hl7.cda.examples | R5 | ImplementationGuide/ImplementationGuide-hl7.cda.examples.json | CDA Examples | active | 2025-02 | examples | |||
| hl7.fhir.us.pcs | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.pcs.json | United States Patient Care Summary (US-PCS) Implementation Guide | trial-use | 2 | cgp | 2026-09 | us | |
| hl7.fhirpath | R4 | ImplementationGuide/ImplementationGuide-hl7.fhirpath.json | FHIRPath Specification | normative | 2026-10 | uv | |||
| hl7.fhir.uv.smart-scheduling-links | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.uv.smart-scheduling-links.json | SMART Scheduling Links | trial-use | 2 | pa | 2026-10 | uv | |
| hl7.fhir.us.vrdr | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.vrdr.json | Vital Records Death Reporting (VRDR) FHIR Implementation Guide | active | pher | 2024-10 | us | ||
| hl7.fhir.eu.imaging-api | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.eu.imaging-api.json | EU Health Access API for Imaging Reports | draft | 2026-10 | eu | |||
| ru.core | R5 | ImplementationGuide/ImplementationGuide-ru.core.json | RuCoreIG | active | 2026-09 | ||||
| fhir.nl.clientbeeld360 | R4 | ImplementationGuide/ImplementationGuide-fhir.nl.clientbeeld360.json | Netherlands - Clientbeeld 360 Implementation Guide | active | 2026-09 | us | |||
| hl7.at.fhir.tc.wg.scheduling.r5 | R5 | ImplementationGuide/ImplementationGuide-hl7.at.fhir.tc.wg.scheduling.r5.json | Austrian Appointment Scheduling (R5) | draft | 2026-09 | ||||
| hl7.fhir.us.home-lab-report | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.home-lab-report.json | At-Home In-Vitro Test Report | active | oo | 2024-08 | us | ||
| hl7.cda.uv.core | R5 | ImplementationGuide/ImplementationGuide-hl7.cda.uv.core.json | Clinical Document Architecture | active | 2023-10 | uv | |||
| hl7.cda.us.ccda | R5 | ImplementationGuide/ImplementationGuide-hl7.cda.us.ccda.json | Consolidated CDA (C-CDA) | active | 2026-06 | us | |||
| hl7.fhir.us.vr-common-library | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.vr-common-library.json | Vital Records Common Library (VRCL) FHIR Implementation Guide | active | pher | 2026-10 | us | ||
| ch.fhir.ig.ch-alis-connect | R4 | ImplementationGuide/ImplementationGuide-ch.fhir.ig.ch-alis-connect.json | CH ALIS Connect (R4) | active | 2026-06 | ch | |||
| fhir.astp.bhp | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.bhp.json | US Behavioral Health Profiles Implementation Guide | active | 2026-02 | us | |||
| hl7.fhir.uv.phd | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.uv.phd.json | Personal Health Device Implementation Guide | trial-use | 2 | dev | 2026-10 | uv | |
| hl7.fhir.uv.pddi | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.uv.pddi.json | Potential Drug-Drug Interaction (PDDI) Clinical Decision Support | trial-use | 3 | cds | 2022-06 | uv | |
| hl7.fhir.uv.oo-incubator | R6 | ImplementationGuide/ImplementationGuide-hl7.fhir.uv.oo-incubator.json | OO Incubator Implementation Guide | trial-use | 1 | oo | 2026-10 | uv | |
| hl7.fhir.us.davinci-pr | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.davinci-pr.json | Da Vinci Postable Remittance | trial-use | 1 | claims | 2025-04 | us | |
| hl7.fhir.us.vdor | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.us.vdor.json | Violent Death and Overdose Reporting (VDOR) FHIR Implementation Guide | draft | 0 | pher | 2026-05 | us | |
| hl7.fhir.uv.ichom-breast-cancer | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.uv.ichom-breast-cancer.json | ICHOM Patient Centered Outcomes Measure Set for Breast Cancer | trial-use | 2 | 2023-08 | uv | ||
| hl7.cql | R4 | ImplementationGuide/ImplementationGuide-hl7.cql.json | Clinical Quality Language Specification | active | 2026-08 | ||||
| hl7.fhir.uv.ips | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.uv.ips.json | International Patient Summary Implementation Guide | trial-use | 3 | pc | 2026-06 | uv | 3 |
| fhir.nl.zorginzage | R4 | ImplementationGuide/ImplementationGuide-fhir.nl.zorginzage.json | Netherlands - Zorginzage Implementation Guide | active | 2026-10 | us | |||
| hl7.fhir.uv.deqm | R4 | ImplementationGuide/ImplementationGuide-hl7.fhir.uv.deqm.json | Data Exchange For Quality Measures Implementation Guide | trial-use | 4 | cqi | 2026-09 | uv | 8 |
FHIRsmith